Request Demo
Last update 15 Jul 2025
Lamivudine/Tenofovir disoproxil fumarate
Last update 15 Jul 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Lamivudine and Tenofovir disoproxil fumarate, LAMIVUDINE/TENOFOVIR, 拉米夫定/富马酸替诺福韦二吡呋酯 + [3] |
Target |
Action inhibitors |
Mechanism RT inhibitors(Viral reverse transcriptase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (28 Feb 2018), |
RegulationPriority Review (China) |
Login to view timeline
Structure/Sequence
Molecular FormulaC8H11N3O3S |
InChIKeyJTEGQNOMFQHVDC-NKWVEPMBSA-N |
CAS Registry134678-17-4 |
View All Structures (2)
Related
10
Clinical Trials associated with Lamivudine/Tenofovir disoproxil fumarateCTR20241998
拉米夫定替诺福韦片（300mg/300mg）在健康受试者中随机、开放、两制剂、单次给药、两周期、两序列空腹和餐后状态下的生物等效性试验
[Translation] A randomized, open-label, two-dose, single-dose, two-cycle, two-sequence bioequivalence study of lamivudine and tenofovir tablets (300 mg/300 mg) in healthy subjects under fasting and fed conditions
NCT05630872
Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis
NCT07006246
Utilizing Private Pharmacies to Initiate High Risk Young Women and Men on Pre-exposure Prophylaxis (PrEP) in South Africa
100 Clinical Results associated with Lamivudine/Tenofovir disoproxil fumarate
Login to view more data
100 Translational Medicine associated with Lamivudine/Tenofovir disoproxil fumarate
Login to view more data
100 Patents (Medical) associated with Lamivudine/Tenofovir disoproxil fumarate
Login to view more data
1
Literatures (Medical) associated with Lamivudine/Tenofovir disoproxil fumarate01 Dec 2014The Pediatric infectious disease journalQ4 · MEDICINE
Pharmacokinetics of Atazanavir/Ritonavir Among HIV-infected Thai Children Concomitantly Taking Tenofovir Disoproxil Fumarate
Q4 · MEDICINE
Article
Author: Torsak Bunupuradah ; Chonnamet Techasaensiri ; Jintanat Ananworanich ; Amornrat Srimuan ; Siriwan Keadpudsa ; Wasana Prasitsuebsai ; Narukjaporn Thammajaruk ; Thaintip Sahakijpicharn ; Thanyawee Puthanakit
BACKGROUND:
Atazanavir/ritonavir (ATV/r) is a recommended once-daily protease inhibitor. Tenofovir disoproxil fumarate (TDF) can reduce ATV exposure. The authors studied ATV pharmacokinetic (PK) parameters among children who received atazanavir/ritonavir co-administered with TDF.
METHODS:
HIV-infected children aged 6-18 years with a body weight of 25-50 kg were eligible. Branded ATV 200 mg/capsule was taken with generic ritonavir 100 mg/tablet once daily plus TDF and lamivudine. A 24-hour PK study was performed at week 4 at t = 0 (pre-dose), 2, 4, 6, 8, 10, 12 and 24 hours. PK parameters were calculated using non-compartmental methods with WinNonlin software. Targeted ATV AUC 0-24 was 15 mg h/L and C trough was 0.15 mg/L. Comparisons of geometric means of ATV PK parameters between different weight bands were made using regression models.
RESULTS:
Eighteen HIV-infected children with a median (IQR) age of 13 (11-14) years were enrolled. Median (range) body weight and body surface area were 35 (25-42) kg and 1.21 (0.96-1.35) m2, respectively. Median (IQR) CD4 cell count was 735 (540-1233) cells/mm3. Median (range) of ATV was 164 (145-209) mg/m2. Geometric mean (SD) ATV AUC 0-24 was 35.05 (1.06) mg h/L, and ATV C trough was 0.31 (1.13) mg/L. No child had ATV AUC 0-24 or C trough below target levels. There were no significant differences in PK parameters among weight bands.
CONCLUSION:
Atazanavir/ritonavir 200/100 mg dosing provided adequate ATV AUC 0-24 when used with TDF in HIV-infected Thai children weighing between 25 and 50 kg.
100 Deals associated with Lamivudine/Tenofovir disoproxil fumarate
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hepatitis B, Chronic | China | 15 Jan 2019 | |
| HIV Infections | United States | 28 Feb 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | 35 | qnqufbyhvv(nkggvvqilq) = yzwkpouowj cpouxmloki (rtjgzxjiii ) View more | - | 01 Jan 2016 | |||
qnqufbyhvv(nkggvvqilq) = oyimiajiwr cpouxmloki (rtjgzxjiii ) View more | |||||||
Not Applicable | 18 | Atazanavir/ritonavir 200/100 mg | bommtdphha(wmenyjvbat) = wrqzuzfwdz swcnznuvbh (pqvpmsozpw ) | - | 01 Dec 2014 | ||
Not Applicable | - | - | awtdonpfcc(mxyyqhrtyf) = pctbjsmkni rfsboyfbyz (iylnfohkku ) View more | - | 01 Jan 2004 | ||
awtdonpfcc(mxyyqhrtyf) = neyeadmrvc rfsboyfbyz (iylnfohkku ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free